NEW YORK (GenomeWeb News) — Xoma today said it will create monoclonal antibody agents for SRI International as part of that company’s deal with the National Institute of Allergy and Infectious Disease.
 
Xoma said the firms are still negotiating their contract, which will span 5 years and could be worth as much as $28.1 million. The company added that, if the full contract is awarded it will bring to $60 million the total amount of government contracts it has received since 2005.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.